Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.
2.

Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis.

Liu Y, Yin TJ, Zhou R, Zhou S, Fan L, Zhang RG.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1125-32. doi: 10.1007/s00280-013-2299-2. Epub 2013 Sep 26. Review.

PMID:
24067998
3.

Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis.

Wang T, Chuan Pan C, Rui Yu J, Long Y, Hong Cai X, De Yin X, Qiong Hao L, Li Luo L.

PLoS One. 2013 Sep 10;8(9):e74284. doi: 10.1371/journal.pone.0074284. eCollection 2013.

4.

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.

Takezawa K, Okamoto I, Okamoto W, Takeda M, Sakai K, Tsukioka S, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K.

Br J Cancer. 2011 May 10;104(10):1594-601. doi: 10.1038/bjc.2011.129. Epub 2011 Apr 12.

5.
6.

Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.

Sun JM, Ahn JS, Jung SH, Sun J, Ha SY, Han J, Park K, Ahn MJ.

J Clin Oncol. 2015 Aug 1;33(22):2450-6. doi: 10.1200/JCO.2014.59.9324. Epub 2015 Jun 29.

PMID:
26124486
7.

Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.

Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH, Yu CJ, Yang PC.

Lung Cancer. 2011 Oct;74(1):132-8. doi: 10.1016/j.lungcan.2011.01.024. Epub 2011 Mar 1.

PMID:
21367480
8.

Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.

Nicolson MC, Fennell DA, Ferry D, O'Byrne K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, André V, Nguyen TS, Myrand SP, Visseren-Grul C, Das M, Kerr KM.

J Thorac Oncol. 2013 Jul;8(7):930-9. doi: 10.1097/JTO.0b013e318292c500.

9.
10.

Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.

Christoph DC, Asuncion BR, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Wynes MW, Gauler TC, Wohlschlaeger J, Hoiczyk M, Schuler M, Eberhardt WE, Hirsch FR.

J Thorac Oncol. 2013 Jan;8(1):19-30. doi: 10.1097/JTO.0b013e31827628ff.

12.

Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.

Kasai D, Ozasa H, Oguri T, Miyazaki M, Uemura T, Takakuwa O, Kunii E, Ohkubo H, Maeno K, Niimi A.

Anticancer Res. 2013 May;33(5):1935-40.

PMID:
23645741
13.

TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.

Uramoto H, Onitsuka T, Shimokawa H, Hanagiri T.

Anticancer Res. 2010 Oct;30(10):4309-15.

PMID:
21036757
14.

Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.

Igawa S, Ryuge S, Wada M, Otani S, Maki S, Takakura A, Katono K, Sasaki J, Sato Y, Masuda N.

Chemotherapy. 2012;58(4):313-20. doi: 10.1159/000343048. Epub 2012 Nov 7.

PMID:
23147191
15.

[A brief overview of a lung cancer biomarker: thymidylate synthase].

Rouquette I, Mazieres J.

Rev Mal Respir. 2011 Jun;28(6):773-7. doi: 10.1016/j.rmr.2010.12.009. Epub 2011 May 14. Review. French.

PMID:
21742238
16.

Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.

Frings V, van der Veldt AA, Boellaard R, Herder GJ, Giovannetti E, Honeywell R, Peters GJ, Thunnissen E, Hoekstra OS, Smit EF.

PLoS One. 2013 May 24;8(5):e63705. doi: 10.1371/journal.pone.0063705. Print 2013.

17.

Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study.

Fennell DA, Myrand SP, Nguyen TS, Ferry D, Kerr KM, Maxwell P, Moore SD, Visseren-Grul C, Das M, Nicolson MC.

PLoS One. 2014 Sep 24;9(9):e107455. doi: 10.1371/journal.pone.0107455. eCollection 2014.

18.

Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.

Righi L, Papotti MG, Ceppi P, Billè A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, Selvaggi G.

J Clin Oncol. 2010 Mar 20;28(9):1534-9. doi: 10.1200/JCO.2009.25.9275. Epub 2010 Feb 22.

PMID:
20177021
19.

Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed.

Arévalo E, Castañón E, López I, Salgado J, Collado V, Santisteban M, Rodríguez-Ruiz M, Martín P, Zubiri L, Patiño-García A, Rolfo C, Gil-Bazo I.

J Transl Med. 2014 Apr 14;12:98. doi: 10.1186/1479-5876-12-98.

20.

Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.

Kawabata S, Chiang CT, Tsurutani J, Shiga H, Arwood ML, Komiya T, Gills JJ, Memmott RM, Dennis PA.

Oncotarget. 2014 Feb 28;5(4):1062-70.

Supplemental Content

Support Center